Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Praxis Precision Medicines (PRAX) Non-Current Deffered Revenue (2022 - 2024)

Praxis Precision Medicines has reported Non-Current Deffered Revenue over the past 3 years, most recently at $293000.0 for Q3 2024.

  • Quarterly results put Non-Current Deffered Revenue at $293000.0 for Q3 2024, down 80.67% from a year ago — trailing twelve months through Sep 2024 was $293000.0 (down 80.67% YoY), and the annual figure for FY2023 was $1.2 million, down 46.79%.
  • Non-Current Deffered Revenue for Q3 2024 was $293000.0 at Praxis Precision Medicines, down from $588000.0 in the prior quarter.
  • Over the last five years, Non-Current Deffered Revenue for PRAX hit a ceiling of $2.2 million in Q4 2022 and a floor of $293000.0 in Q3 2024.
  • Median Non-Current Deffered Revenue over the past 3 years was $1.3 million (2023), compared with a mean of $1.2 million.
  • Biggest five-year swings in Non-Current Deffered Revenue: plummeted 46.79% in 2023 and later plummeted 80.67% in 2024.
  • Praxis Precision Medicines' Non-Current Deffered Revenue stood at $2.2 million in 2022, then tumbled by 46.79% to $1.2 million in 2023, then plummeted by 74.76% to $293000.0 in 2024.
  • The last three reported values for Non-Current Deffered Revenue were $293000.0 (Q3 2024), $588000.0 (Q2 2024), and $866000.0 (Q1 2024) per Business Quant data.